Everolimus-exemestane (EE) vs palbociclib-letrozole (PL) or palbociclib-fulvestrant (PF) in the treatment of metastatic HR+, HER2- breast cancer. Indirect comparisons with network meta-analysis for daily clinical practice

Autor:	Maximilian Papi, Arcangeli, L. Stocchi, Lorenzo Gianni, Davide Tassinari, C. Cherubini, M. Nicolini, A. Polselli, Ornella Carminati, Carlotta Santelmo
Rok vydání:	2017
Předmět:	Oncology Gynecology medicine.medical_specialty Everolimus Fulvestrant business.industry Letrozole Hematology Palbociclib medicine.disease Clinical Practice chemistry.chemical_compound Breast cancer Exemestane chemistry Meta-analysis Internal medicine Medicine business medicine.drug
Zdroj:	Annals of Oncology. 28:vi37
ISSN:	0923-7534
DOI:	10.1093/annonc/mdx424.042
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::11c17d63927a8cf4fcbefe80c8551ce9 https://doi.org/10.1093/annonc/mdx424.042 Zobrazit plný text záznamu